Committed to providing comprehensive support for global drug development

As a low-affinity adenosine receptor, ADORA3 shows low expression in normal tissues but is strongly upregulated in inflammatory, ischemic and tumor microenvironments. It couples to Gi/o proteins: adenosine binding suppresses adenylate cyclase and reduces cellular cAMP, while Gβγ dimers activate PI3Kγ/Akt/mTOR and MAPK (ERK/p38) signaling. Sustained receptor activation recruits β-arrestin, driving receptor internalization and NF-κB-mediated pro-inflammatory responses.Our ADORA3 stable cell lines have been validated in cAMP and β-arrestin assays to support your drug discovery programs.